2025
Impact of Abatacept Inclusive Graft Versus Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy
Shah N, Ngwube A, Suresh T, Sowa A, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Dalal J, Grimley M, Jacobsohn D, Kamani N, Krajewski J, Krishnamurti L, Saini S, Skiles J, Shenoy S. Impact of Abatacept Inclusive Graft Versus Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplantation And Cellular Therapy 2025 PMID: 40543708, DOI: 10.1016/j.jtct.2025.06.015.Peer-Reviewed Original ResearchGraft-versus-host diseaseChronic graft-versus-host diseaseHematopoietic cell transplantationGraft-versus-host disease prophylaxisGVHD prophylaxisAbatacept groupCell transplantationIncidence of posterior reversible encephalopathy syndromeSeverity of graft-versus-host diseasePresence of graft-versus-host diseasePosterior reversible encephalopathy syndromeAllogeneic hematopoietic cell transplantationSibling donor hematopoietic cell transplantationDonor hematopoietic cell transplantationDonor-derived hematopoiesisImmune reconstitution patternsReduced intensity conditioningEvent-free survivalGraft-versus-hostHost disease prophylaxisReversible encephalopathy syndromeSystemic immune suppressionStem cell transplantationPrimary graft rejectionPediatric stem cell transplantationComparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease
Prior D, Liang J, Deng Y, Shah N, Flagg A, Krishnamurti L. Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2025 PMID: 40379050, DOI: 10.1016/j.jtct.2025.05.004.Peer-Reviewed Original ResearchGraft-versus-host diseaseHematopoietic cell transplantationHLA-matched related donorSickle cell diseaseConditioning regimen intensityAnti-thymocyte globulinEFS ratesConditioning regimensRegimen intensityCell transplantationRate of chronic graft-versus-host diseaseRelated donorsChronic graft-versus-host diseaseHematopoietic cell transplantation regimensNon-myeloablative conditioning regimensAllogeneic hematopoietic cell transplantationCell diseaseComparison of regimensMyeloablative conditioning regimensNon-myeloablative conditioningNon-myeloablative regimensSickle cell disease patientsEvent-free survivalGraft-versus-hostAnti-thymocyteClinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Gurnari C, Robin M, Adès L, Aljurf M, Almeida A, Duarte F, Bernard E, Cutler C, Della Porta M, De Witte T, DeZern A, Drozd-Sokolowska J, Duncavage E, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian R, Hellström-Lindberg E, Jacoby M, Kulasekararaj A, Lindsley R, Maciejewski J, Makishima H, Malcovati L, Mittelman M, Myhre A, Ogawa S, Onida F, Papaemmanuil E, Passweg J, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso M, Yakoub-Agha I, Zeidan A, Walter M, Kröger N, McLornan D, Cazzola M. Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT. Blood 2025, 145: 1987-2001. PMID: 39970324, DOI: 10.1182/blood.2024025131.Peer-Reviewed Original ResearchAllo-HCTMolecular International Prognostic Scoring SystemGenomic profilingInternational Prognostic Scoring SystemAllogeneic hematopoietic cell transplantationAssociated with superior clinical outcomesMutant hematopoietic cellsNon-transplant therapiesPrognostic scoring systemHematopoietic cell transplantationClinical practiceTime of diagnosisSuperior clinical outcomesEstimate patient survivalIPSS-MAllo-HSCTCell transplantationExpert international panelPatient survivalPredisposition variantsTherapeutic optionsClinical outcomesCurative treatmentGenetic abnormalitiesHematopoietic cellsTeduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey
Brehm N, Biavasco F, Clausen J, Jung J, Maas-Bauer K, Wäsch R, Verbeek M, Nuernbergk C, Ihorst G, Seropian S, Finke J, Gowda L, Sidlik Muskatel R, Peffault de Latour R, Socie G, Wehr C, Michonneau D, Zeiser R. Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey. Bone Marrow Transplantation 2025, 60: 873-878. PMID: 40229535, PMCID: PMC12151853, DOI: 10.1038/s41409-025-02586-2.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-2Non-relapse mortalityIntestinal acute graft-versus-host diseaseLevels of glucagon-like peptide-2Acute graft-versus-host diseaseGraft-versus-host diseaseMulticenter surveyAllogeneic hematopoietic cell transplantationRetrospective multicenter surveyHematopoietic cell transplantationFraction of patientsAlbumin serum levelsIntestinal stem cellsGVHD severitySR-aGVHDTeduglutide treatmentAcute GVHDAllo-HCTCell transplantationProspective trialsPreclinical dataSerum levelsTreated patientsRetrospective analysisFollow-upTSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Pineiro L, Gill S, Gowda L, Uberti J, White T, Wang Y, Nguyen C, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation And Cellular Therapy 2025, 31: s59-s60. DOI: 10.1016/j.jtct.2025.01.096.Peer-Reviewed Original ResearchRIC HCTReduced intensity conditioningHematopoietic cell transplantationRelapse-free survivalPost-HCTControl subjectsControl armDonor chimerismGrade II-IV acute graft-versus-host diseaseII-IV acute graft-versus-host diseaseT cell receptor-engineered T cellsAcute graft-versus-host diseasePhase 1 dose-escalation studyIncreased relapse-free survivalGraft-versus-host diseaseAllogeneic hematopoietic cell transplantationNon-relapse deathPost-HCT MRDEngineered T cellsCytokine release syndromeData cut-offMonths post-HCTReducing relapse ratesYears post-HCTAssessment of efficacy
2024
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Nishino J, Hu W, Kishtagari A, Shen B, Gao X, Blackman C, Kassim A, Marneni N, Cherukuri A, Vittrup R, Kalkan F, Shah R, Ahn C, Gao A, Ahmedrabie A, Collins R, Zeidan A, Bidikian A, Gowda L, Shaffer B, Madanat Y, Zhao Z, Chung S, Morrison S. Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants. Cancer Discovery 2024, 15: 748-766. PMID: 39786370, PMCID: PMC11962394, DOI: 10.1158/2159-8290.cd-24-0719.Peer-Reviewed Original ResearchAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationB-blockersCell transplantationHematopoietic regenerationGraft-versus-host disease prophylaxisAutologous hematopoietic cell transplantationDelayed platelet engraftmentImpaired hematopoietic regenerationPost-transplant chemotherapyGraft-versus-hostAdrenergic receptor signalingBone marrow regenerationInhibitory effectPlatelet engraftmentInhibit engraftmentReceptor inhibitorsDisease prophylaxisMarrow regenerationMouse hematopoiesisHematopoietic cellsEngraftmentLarger dosesReceptor signalingPeripheral nervesLeukemia Physician's Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
Moreno Vanegas Y, El Khatib S, Hisrich B, Coltoff A, Shallis R, Patel A, Bewersdorf J, Oh T, Abaza Y, Foucar C, Goldberg A, Duvall A, Atallah E, Litzow M, Badar T. Leukemia Physician's Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia. Blood 2024, 144: 1487-1487. DOI: 10.1182/blood-2024-205782.Peer-Reviewed Original ResearchAcute myeloid leukemiaTP53-mAllo-HCTComplex cytogeneticsHypomethylating agentsInternational consensus classificationRefractory diseaseSecondary AMLOverall survivalMyeloid leukemiaTP53-mutated acute myeloid leukemiaDe novo acute myeloid leukemiaProgressive acute myeloid leukemiaSecondary acute myeloid leukemiaAllogeneic hematopoietic cell transplantationMedian overall survivalTP53 allelic stateIncomplete count recoveryLow-intensity regimensReviewed electronic medical recordsHematopoietic cell transplantationRate of relapseMulticenter observational studyOverall response ratePatient selection criteriaRandomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Larkin K, Pandit-Taskar N, Rowley S, Munshi P, Cook R, Levy M, Lazarus H, Sandmaier B, Pagel J, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. Journal Of Clinical Oncology 2024, 43: 201-213. PMID: 39298738, PMCID: PMC11709001, DOI: 10.1200/jco.23.02018.Peer-Reviewed Original ResearchEvent-free survivalIntention-to-treat populationIntention-to-treatHazard ratioRR-AMLOverall survivalOlder patientsPhase III open-label trialEvent-free survival HRTreatment-related adverse eventsAllogeneic hematopoietic cell transplantationConventional careIncomplete platelet recoveryOS hazard ratioSecondary end pointsHematopoietic cell transplantationOpen-label trialConventional care groupPretransplant regimenRefractory AMLRelapsed/refractory AMLChemotherapy initiationDismal prognosisPlatelet recoveryCell transplantationLong-Term Follow-Up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial
Seropian S, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Vusirikala M, Sandmaier B, Pagel J, Desai A, Giralt S. Long-Term Follow-Up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s173. DOI: 10.1016/s2152-2650(24)00518-4.Peer-Reviewed Original ResearchAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationR/R AMLCell transplantationEfficacy benefitsOlder patientsAML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial
Seropian S, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Vusirikala M, Sandmaier B, Pagel J, Desai A, Giralt S. AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s319. DOI: 10.1016/s2152-2650(24)01210-2.Peer-Reviewed Original ResearchAllogeneic hematopoietic cell transplantationR/R AMLHematopoietic cell transplantationFollow-upOverall survivalCell transplantationCC patientsCurative allogeneic hematopoietic cell transplantationOlder patientsControlled phase 3 studiesRefractory acute myeloid leukemiaConventional careMedian overall survivalR/R AML patientsMedian Follow-UpTotal body irradiationBaseline patient characteristicsAcute myeloid leukemiaAnalysis of efficacyOff-target toxicityLong-term survivorsCD45-expressing cellsData cutoffBody irradiationMucositis ratesSystematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation
Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Díaz-Fernández P, Gómez-García de Soria V, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh K, Powell K, Ji H, Hernandez G, Abelin J, Klaeger S, Forman C, Clauser K, Sarkizova S, Braun D, Penter L, Kim H, Lane W, Oliveira G, Kean L, Li S, Livak K, Carr S, Keskin D, Muñoz-Calleja C, Ho V, Ritz J, Soiffer R, Neuberg D, Stewart C, Getz G, Wu C. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nature Biotechnology 2024, 43: 971-982. PMID: 39169264, PMCID: PMC11912513, DOI: 10.1038/s41587-024-02348-3.Peer-Reviewed Original ResearchAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationCell transplantationEffect of allogeneic hematopoietic cell transplantationIdentification of minor histocompatibility antigensOutcomes of allogeneic hematopoietic cell transplantationOccurrence of acute GVHDPost-transplant disease recurrenceGraft-versus-host diseaseWhole-exome sequencing of germline DNASequencing of germline DNAGraft-versus-leukemiaT-cell alloreactivityGraft-versus-hostMinor histocompatibility antigensWhole-exome sequencingAcute GVHDPulmonary GVHDAllo-HCTDisease recurrenceHistocompatibility antigensClinical outcomesValidation cohortGermline DNAGVHDOncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice
Talvard-Balland N, Braun L, Dixon K, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher L, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert A, Schramm M, Cheng Y, Köttgen A, Duyster J, Menssen H, Ritz J, Blazar B, Boerries M, Graeff A, Sariipek N, van Galen P, Buescher J, Cabezas-Wallscheid N, Pahl H, Pearce E, Soiffer R, Wu C, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo V, Zeiser R. Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. Journal Of Clinical Investigation 2024, 134: e177460. PMID: 38916965, PMCID: PMC11324309, DOI: 10.1172/jci177460.Peer-Reviewed Original ResearchAcute graft-versus-host diseaseAcute myeloid leukemiaPost-allo-HCTTim-3GVL effectLigand expressionGraft-versus-host diseaseAllogeneic hematopoietic cell transplantationCD8+ T cellsEnhanced GVL effectIFN-g productionLow ligand expressionTim-3 ligandAnti-PD-1TIM-3 blockadeAnti-Tim-3Hematopoietic cell transplantationSurvival of miceCells of patientsAllo-HCTLeukemia relapseCell transplantationCause of deathMyeloid leukemiaT cellsTrajectories of patient-reported outcomes after prolonged stays for hematopoietic cell transplant.
Gao L, DeFilipp Z, Chen Y, Lee S, LeBlanc T, Amonoo H, El-Jawahri A, Newcomb R. Trajectories of patient-reported outcomes after prolonged stays for hematopoietic cell transplant. Journal Of Clinical Oncology 2024, 42: 6553-6553. DOI: 10.1200/jco.2024.42.16_suppl.6553.Peer-Reviewed Original ResearchHematopoietic cell transplantationProlonged length of stayAllogeneic hematopoietic cell transplantationPosttraumatic stress disorderBaseline to week 2Patient-reported outcomesDepressive symptomsQuality of lifeWeek 2Cell transplantationAcute leukemiaChronic graft-versus-host diseaseGraft-versus-host diseaseAutologous hematopoietic cell transplantationYears of hematopoietic cell transplantationProspective study of patientsPsychological distressPosttraumatic stress disorder symptomsRate of relapseMonths post-HCTStudy of patientsMultivariate logistic regressionAssociated with greater oddsLength of stayIncreased psychological distressA phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
Al Malki M, Keyzner A, Suh H, Popat U, Gill S, Chen Y, Solh M, Gowda L, Buonomo E, Wang Y, Murray J, MacBeath G, Barton D, Chattopadhyay S, Reshef R. A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Journal Of Clinical Oncology 2024, 42: tps2678-tps2678. DOI: 10.1200/jco.2024.42.16_suppl.tps2678.Peer-Reviewed Original ResearchHematopoietic cell transplantationMinimal residual diseaseEngineered T cell therapiesPatient hematopoietic cellsT-cell therapyMinor histocompatibility antigensHematopoietic cellsHLA-A*02:01Residual diseaseCell transplantationHematologic malignanciesPost-HCTT cellsHistocompatibility antigensTreatment armsCAR-T cell therapyAllogeneic hematopoietic cell transplantationHematopoietic cell transplant patientsPrevent disease relapseRelapse post-HCTDose-limiting toxicityDisease-free survivalEngineered T cellsHaploidentical donor transplantationSurrogate of efficacyOutcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects
Newcomb R, Gao L, Vanderklish J, Tse A, Saylor M, Danielson C, Wali N, Frigault M, McAfee S, Spitzer T, DeFilipp Z, Chen Y, Amonoo H, El-Jawahri A. Outcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects. Transplantation And Cellular Therapy 2024, 30: 700-711. PMID: 38685402, PMCID: PMC11223964, DOI: 10.1016/j.jtct.2024.04.018.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationAllogeneic hematopoietic cell transplantationPromote screening adherencePost-HCTScreening adherenceCell transplantationPost-transplant complicationsSurvivorship programsCox proportional hazards regressionProportion of patientsPulmonary function testsProportional hazards regressionEndocrine evaluationMedian timeSecondary cancersRetrospective analysisEvaluate efficacyPrimary outcomeHazards regressionFunction testsPatientsLate effectsScreening outcomesScreening domainsTransfer careCost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia
Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.Peer-Reviewed Original ResearchQuality-adjusted life yearsCompletion of consolidation therapyFLT3-mutant acute myeloid leukemiaAllogeneic hematopoietic cell transplantationIncremental cost-effectiveness ratioProbabilistic sensitivity analysesImproved overall survivalHematopoietic cell transplantationPartitioned survival analysis modelAcute myeloid leukemiaCost-effectiveness ratioFLT3 inhibitor quizartinibHealth economic implicationsConsolidation therapyInduction chemotherapyAverage wholesale priceOverall survivalCell transplantationContinuous therapyMyeloid leukemiaITD mutationQuizartinibIncremental costCost-effective optionLife years131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML
Nath R, Seropian S, Gyurkocza B, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, van Besien K, Schuster M, Law A, Spross J, Li K, Nagl N, Vusirikala M, Nahar A, Desai A, Tomlinson B. 131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML. Transplantation And Cellular Therapy 2024, 30: s54-s55. DOI: 10.1016/j.jtct.2023.12.089.Peer-Reviewed Original ResearchHematopoietic cell transplantationPrimary induction failureAcute myeloid leukemiaHigh-risk featuresNon-relapse mortalityCR/CRp ratesInduction failureCurative allogeneic hematopoietic cell transplantationAcute myeloid leukemia ptsAdverse cytogenetic risk groupControlled phase 3 studiesEradication of leukemic cellsRefractory acute myeloid leukemiaAllogeneic hematopoietic cell transplantationCC armCytogenetic risk groupMultiple high-risk featuresTotal body irradiationPhase 3 studyConventional careHigh-risk populationCompared to 0%BCL2 inhibitorsBody irradiationCell transplantation131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes
Foran J, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Nagl N, Brodin P, Vusirikala M, Nahar A, Sandmaier B, Pagel J, Giralt S, Desai A, Seropian S. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes. Transplantation And Cellular Therapy 2024, 30: s110-s111. DOI: 10.1016/j.jtct.2023.12.174.Peer-Reviewed Original ResearchHematopoietic cell transplantationAllogeneic hematopoietic cell transplantationTP53 mutationsMedian OSOverall survivalPositive PTCell transplantationCC groupDays post-hematopoietic cell transplantationControlled phase 3 studiesEradication of leukemic cellsPost-hematopoietic cell transplantationImprove outcomesConventional careMedian overall survivalTotal body irradiationPhase 3 studyOutcomes of PTPost Hoc AnalysisR/R AMLBody irradiationAML patientsPrimary endpointCurative therapyRelapse rateDose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML
Chen G, Abboud C, Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Leung E, Chen M, Natwa M, Spross J, Li K, Desai A, Wahl R, Brodin P, Pandit-Taskar N. Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML. Transplantation And Cellular Therapy 2024, 30: s114-s115. DOI: 10.1016/j.jtct.2023.12.180.Peer-Reviewed Original ResearchPrimary endpointBone marrowLiver doseDose responseCurative allogeneic hematopoietic cell transplantationDose toleranceControlled phase 3 studiesEradication of leukemic cellsRate of hematologic toxicityAllogeneic hematopoietic cell transplantationConventional careTotal body irradiationPhase 3 studyHematopoietic cell transplantationRadiation dose toleranceDiseased bone marrowDoses to liverRadiation dose responseDose-response relationshipDose to target tissuesRadiation dose to liverAcute GVHDR/R AMLHematologic toxicityComplete remissionTargeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment
Choe H, Nath R, Seropian S, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, van Besien K, Schuster M, Law A, Spross J, Li K, Nagl N, Vusirikala M, Nahar A, Desai A, Gyurkocza B. Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment. Transplantation And Cellular Therapy 2024, 30: s59-s60. DOI: 10.1016/j.jtct.2023.12.094.Peer-Reviewed Original ResearchHematopoietic cell transplantationAllogeneic hematopoietic cell transplantationTime to neutrophilCC armChronic GVHDDonor chimerismPlatelet engraftmentCell transplantationCumulative incidenceTherapeutic dosesCumulative incidence of grade III-IV acute graft-versus-host diseaseGrade III-IV acute graft-versus-host diseaseIII-IV acute graft-versus-host diseaseIncidence of grade III-IV acute graft-versus-host diseaseCumulative incidence of chronic GVHDCurative allogeneic hematopoietic cell transplantationDays post-hematopoietic cell transplantationAcute graft-versus-host diseaseControlled phase 3 studiesEradication of leukemic cellsGrade III-IV GvHDIncidence of chronic GVHDRadiation dose to marrowGraft-versus-host diseaseMedian time to neutrophil
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply